|
|
|
|
|
|
|
|
|
|
|
 
|
Pancreas Cancer News and Archives |
|
 |
For educational purposes only; not to be relied upon. Please read Pancreatica Disclaimer | |
| September 30, 2002 | Meat Intake and Cooking Techniques: Associations with Pancreatic Cancer | |
| September 23, 2002 | Phase II Study to Evaluate Combining Gemcitabine with Flutamide in Advanced Pancreatic Cancer Patients | |
| September 15, 2002 | Farnesyl Transferase Inhibitors: A Major Breakthrough in Anticancer Therapy? | |
| September 15, 2002 | High-Intensity Focused Ultrasound in Patients with Late-Stage Pancreatic Carcinoma | |
| September 15, 2002 | Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily | |
| September 15, 2002 | The Role of PET in Localization of Neuroendocrine and Adrenocortical Tumors | |
| September 4, 2002 | Onyx and Bayer Initiate Phase II Studies of Raf Kinase Inhibitor | |
| September 4, 2002 | Pancreaticoduodenectomy for Islet Cell Tumors of the Head of the Pancreas: Long-term Survival Analysis | |
| September 4, 2002 | Regular Use of Aspirin and Pancreatic Cancer Risk | |
| September 4, 2002 | Videolaparoscopic Resection of Insulinomas: Experience in Two Institutions | |
| September 1, 2002 | Diagnosis and Staging of Pancreatic Cancer: Comparison of Mangafodipir Trisodium-Enhanced MR Imaging and Contrast-Enhanced Helical Hydro-CT | |
| September 1, 2002 | Gemcitabine, Paclitaxel, and Radiation for Locally Advanced Pancreatic Cancer: A Phase I Trial | |
| September 1, 2002 | Pancreaticoduodenectomy With or Without Distal Gastrectomy and Extended Retroperitoneal Lymphadenectomy for Periampullary Adenocarcinoma, Part 2: Randomized Controlled Trial Evaluating Survival, Morbidity, and Mortality | |
| September 1, 2002 | Selection of Pancreaticojejunostomy Techniques According to Pancreatic Texture and Duct Size | |
| August 27, 2002 | Differential Diagnosis Between Chronic Pancreatitis and Pancreatic Cancer: Value of the Detection of KRAS2 Mutations in Circulating DNA | |
| August 27, 2002 | Weekly Gemcitabine Plus Epirubicin as Effective Chemotherapy for Advanced Pancreatic Cancer: A Multicenter Phase II Study | |
| August 19, 2002 | Aphton Announces Application for Fast Track Designation Filed With FDA For Its Anti-Gastrin Immunogen G17DT for Treatment of Pancreatic Cancer | |
| August 15, 2002 |
A Phase II Single Institutional Experience with Preoperative Radiochemotherapy in Pancreatic Adenocarcinoma |
|
| August 15, 2002 | Adjuvant Radiotherapy in Resectable Pancreatic Carcinoma | |
| August 15, 2002 | Gemcitabine and Platinum Combinations in Pancreatic Cancer | |
| August 15, 2002 | New Applications of Gemcitabine and Future Directions in the Management of Pancreatic Cancer | |
| August 15, 2002 | The Pemetrexed/Gemcitabine Combination in Pancreatic Cancer | |
| August 7, 2002 | Association Between Nonsteroidal Anti-Inflammatory Drug Use and the Incidence of Pancreatic Cancer | |
| August 6, 2002 | Aspirin May Ward Off Pancreas Cancer | |
| August 1, 2002 | A Phase II Study of Gemcitabine and Tamoxifen in Advanced Pancreatic Cancer | |
| August 1, 2002 | Gene Therapy for Pancreatic Cancer Using an Adenovirus Vector Encoding Soluble flt-1 Vascular Endothelial Growth Factor Receptor | |
| August 1, 2002 | Palliative Treatment in "Peri"-Pancreatic Carcinoma: Stenting or Surgical Therapy? | |
| August 1, 2002 | Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297 | |
| August 1, 2002 | Radical Resection for Pancreatic Cancer | |
| August 1, 2002 | Surgical Experience with Functioning Pancreatic Neuroendocrine Tumors | |
| August 1, 2002 | Usefulness of EUS-guided Fine Needle Aspiration (EUS-FNA) in the Diagnosis of Functioning Neuroendocrine Tumors | |
| July 18, 2002 | Power Doppler Ultrasonography for the Assessment of Vascular Invasion by Pancreatic Cancer | |
| July 17, 2002 | Aphton Announces FDA Grants Orphan-Drug Status for Its Anti-Gastrin Immunogen G17DT For Treatment of Pancreatic Cancer | |
| July 17, 2002 | GenVec Begins Phase IIb Trials Of TNFerade in Patients With Pancreatic Cancer | |
| July 15, 2002 | Overexpression of the Sm-like Proto-Oncogene in Primary and Metastatic Pancreatic Endocrine Tumors | |
| July 15, 2002 | Paclitaxel as a Radiation Sensitizer for Locally Advanced Pancreatic Cancer | |
| July 15, 2002 | Treatment of Unresectable Pancreatic Carcinoma by Intraluminal Brachytherapy in the Duct of Wirsung | |
| July 1, 2002 | 5-FU, Folinic Acid and Cisplatin (LV5FU2-P) for Unresectable Pancreatic Cancer | |
| July 1, 2002 | A Phase I Study of Weekly Gemcitabine and Docetaxel in Patients with Advanced Cancer: A Hoosier Oncology Group Study | |
| July 1, 2002 | Evaluation of Candidate Genes MAP2K4, MADH4, ACVR1B, and BRCA2 in Familial Pancreatic Cancer: Deleterious BRCA2 Mutations in 17% | |
| July 1, 2002 | Human Aspartyl (Asparaginyl) beta-Hydroxylase Monoclonal Antibodies: Potential Biomarkers for Pancreatic Carcinoma | |
| July 1, 2002 | Palliative MEFLEP Therapy in Advanced Pancreatic Cancer: Excellent Response in a Patient with Her-2/neu Amplification | |
| July 1, 2002 | Targeting Interleukin-4 Receptors for Effective Pancreatic Cancer Therapy | |
| July 1, 2002 | Treatment of Malignant Endocrine Pancreatic Tumors with a Combination of Alpha-Interferon and Somatostatin Analogs | |
|
Meat
Intake and Cooking Techniques: Associations with Pancreatic Cancer [Abstract]
Phase
II Study to Evaluate Combining Gemcitabine with Flutamide in
Advanced Pancreatic Cancer Patients [Abstract]
Farnesyl
Transferase Inhibitors: A Major Breakthrough in Anticancer Therapy?
[Abstract]
High-Intensity
Focused Ultrasound in Patients with Late-Stage Pancreatic Carcinoma [Abstract]
Phase
I Clinical Trial of Recombinant Human Endostatin Administered
as a Short Intravenous Infusion Repeated Daily [Abstract]
The
Role of PET in Localization of Neuroendocrine and Adrenocortical
Tumors [Abstract]
Onyx
and Bayer Initiate Phase II Studies of Raf Kinase Inhibitor Onyx Pharmaceuticals, Inc. today announced that its partner Bayer Corporation has initiated a single-agent Phase II clinical study of a novel cancer agent, BAY 43-9006, a Raf kinase inhibitor, for the potential treatment of hepatocellular carcinoma. Onyx indicated that initiation of the Phase II program earned a $5 million loan milestone payment for Onyx. The companies advised that additional single-agent Phase II studies are planned. Bayer said separately that a Phase II study in colorectal cancer is expected to begin this quarter. ...full article
Pancreaticoduodenectomy
for Islet Cell Tumors of the Head of the Pancreas: Long-term
Survival Analysis [Abstract]
Regular
Use of Aspirin and Pancreatic Cancer Risk [Abstract]
Videolaparoscopic
Resection of Insulinomas: Experience in Two Institutions [Abstract]
Diagnosis
and Staging of Pancreatic Cancer: Comparison of Mangafodipir
Trisodium-Enhanced MR Imaging and Contrast-Enhanced Helical Hydro-CT [Abstract]
Gemcitabine,
Paclitaxel, and Radiation for Locally Advanced Pancreatic Cancer:
A Phase I Trial [Abstract]
Pancreaticoduodenectomy
With or Without Distal Gastrectomy and Extended Retroperitoneal
Lymphadenectomy for Periampullary Adenocarcinoma, Part 2: Randomized
Controlled Trial Evaluating Survival, Morbidity, and Mortality [Abstract]
Selection
of Pancreaticojejunostomy Techniques According to Pancreatic
Texture and Duct Size [Abstract]
Differential
Diagnosis Between Chronic Pancreatitis and Pancreatic Cancer:
Value of the Detection of KRAS2 Mutations in Circulating DNA [Abstract]
Weekly
Gemcitabine Plus Epirubicin as Effective Chemotherapy for Advanced
Pancreatic Cancer: A Multicenter Phase II Study [Abstract]
Aphton
Announces Application for Fast Track Designation Filed With FDA
For Its Anti-Gastrin Immunogen G17DT for Treatment of Pancreatic
Cancer Aphton Corporation announced today that it has filed an application with the FDA for Fast Track designation for its anti-gastrin immunogen G17DT for treatment of pancreatic cancer. ...full article
A
Phase II Single Institutional Experience with Preoperative Radiochemotherapy
in Pancreatic Adenocarcinoma [Abstract]
Adjuvant
Radiotherapy in Resectable Pancreatic Carcinoma [Abstract]
Gemcitabine
and Platinum Combinations in Pancreatic Cancer [Abstract]
New
Applications of Gemcitabine and Future Directions in the Management
of Pancreatic Cancer [Abstract]
The
Pemetrexed/Gemcitabine Combination in Pancreatic Cancer [Abstract]
[Abstract]
Aspirin
May Ward Off Pancreas Cancer Aspirin, already widely used by people hoping to ward off a heart attack, may also be helpful in preventing pancreatic cancer. ...full article
A
Phase II Study of Gemcitabine and Tamoxifen in Advanced Pancreatic
Cancer [Abstract]
Gene
Therapy for Pancreatic Cancer Using an Adenovirus Vector Encoding
Soluble flt-1 Vascular Endothelial Growth Factor Receptor [Abstract]
Palliative
Treatment in "Peri"-Pancreatic Carcinoma: Stenting
or Surgical Therapy? [Abstract]
Phase
III Study of Gemcitabine in Combination With Fluorouracil Versus
Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma:
Eastern Cooperative Oncology Group Trial E2297 [Abstract]
Radical
Resection for Pancreatic Cancer [Abstract]
Surgical
Experience with Functioning Pancreatic Neuroendocrine Tumors [Abstract]
Usefulness
of EUS-guided Fine Needle Aspiration (EUS-FNA) in the Diagnosis
of Functioning Neuroendocrine Tumors [Abstract]
Power
Doppler Ultrasonography for the Assessment of Vascular Invasion
by Pancreatic Cancer [Abstract]
Aphton
Announces FDA Grants Orphan-Drug Status for Its Anti-Gastrin
Immunogen G17DT For Treatment of Pancreatic Cancer Aphton Corporation announced today that it received official notice from the FDA granting its anti-gastrin G17DT Immunogen Orphan-Drug status for treatment of adenocarcinoma of the pancreas. ...full article
GenVec
Begins Phase IIb Trials Of TNFerade in Patients With Pancreatic
Cancer GenVec, Inc., a biopharmaceutical company developing gene-based medicines, today announced the commencement of a randomized, controlled Phase IIb clinical trial for its lead cancer drug, TNFerade, in patients with locally advanced pancreatic cancer. GenVec has now initiated this 17-center Phase IIb clinical trial of TNFerade as a first-line therapy after first reporting Phase Ib data on TNFerade at the American Society of Clinical Oncology (ASCO) annual meeting in May 2002. ...full article
Overexpression
of the Sm-like Proto-Oncogene in Primary and Metastatic Pancreatic
Endocrine Tumors [Abstract]
Paclitaxel
as a Radiation Sensitizer for Locally Advanced Pancreatic Cancer [Abstract]
Treatment
of Unresectable Pancreatic Carcinoma by Intraluminal Brachytherapy
in the Duct of Wirsung [Abstract]
5-FU,
Folinic Acid and Cisplatin (LV5FU2-P) for Unresectable Pancreatic
Cancer [Abstract]
A
Phase I Study of Weekly Gemcitabine and Docetaxel in Patients
with Advanced Cancer: A Hoosier Oncology Group Study [Abstract]
Evaluation
of Candidate Genes MAP2K4, MADH4, ACVR1B, and BRCA2 in Familial
Pancreatic Cancer: Deleterious BRCA2 Mutations in 17% [Abstract]
Human
Aspartyl (Asparaginyl) beta-Hydroxylase Monoclonal Antibodies:
Potential Biomarkers for Pancreatic Carcinoma [Abstract]
Palliative
MEFLEP Therapy in Advanced Pancreatic Cancer: Excellent Response
in a Patient with Her-2/neu Amplification [Abstract]
Targeting
Interleukin-4 Receptors for Effective Pancreatic Cancer Therapy [Abstract]
Treatment
of Malignant Endocrine Pancreatic Tumors with a Combination of
Alpha-Interferon and Somatostatin Analogs [Abstract]
|
||
|
For educational
purposes only and not to be relied upon. Please read Pancreatica
Disclaimer |
||
 Home | In The News | Links | Newswire | Donations FAQ | Clinical Trials Database | Research Resources | About Us |
||
|
|
||
|
www.pancreatica.org |
||
